Menu
Recruiting NCT07141043

Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients

Observational Hemodyalysis Kidney Tansplant Osteoporosis CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Hemodyalysis, Kidney Tansplant, Osteoporosis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder. Basic parameters: 20 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Romania
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients

Overview

This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.

Detailed description

Prospective observational study that will evaluate differences in bone (BMD, TBS, VFA and BTMs, serum calcium and phosphate) parameters in hemodialysis (HD) patients and kidney transplant recipients (KTR), compared to general population osteopenia/osteoporosis patients, at baseline and after one year of monitoring, with or without therapeutic intervention for CKD-MBD (KTR and HD groups).

Primary outcome measures

  • Change in BTM Levels in KTx recipients (KTR) compared to HD patients and general population osteopenia/osteoporosis (GPO) patients. [Time frame: 12 months]
Secondary outcome measures (3)
  • Correlation Between BTM Levels and BMD in KTR compared with HD and GPO patients. [Time frame: 12 months]
  • Correlation Between BTM Levels and TBS in KTR compared with HD and GPO patients. [Time frame: 12 months]
  • Key BTMs Predicting Bone Health Outcomes in KTR Patients [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.
  • KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.
  • GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.

Exclusion criteria

  • HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen/anti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding.
  • KTR group: The same as for HD + return to dialysis + acute graft rejection.
  • GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (>7.5 mg Prednisone or equivalent for at least 3 months).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

Romania · 1 center
  • University of Medicine and Pharmacy "Grigore T. Popa" — Iași

Identifiers

NCT: NCT07141043 · Nr. 501/30.11.2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗